Identifying markers for long-term survival in localized lung cancer
EMT, Reactivation of Embryonic Transcription Factors and Alteration of the miR Signaling Network as Pronostic and Predictive Markers in Lung Cancer
This study is trying to find specific markers in tumor samples from patients with localized lung cancer to see if they can help predict long-term survival after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | European Georges Pompidou Hospital Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT03509779 on ClinicalTrials.gov |
What this trial studies
This research aims to identify an 'EMT signature' that correlates with long-term disease-free survival in patients with non-small cell lung cancer (NSCLC) after surgical treatment. The study will utilize an integrated molecular approach, including DNA, RNA, and miR profiling, to analyze tumor samples from a large cohort of localized NSCLC patients. Additionally, in vitro analyses using lung cancer cell lines will be conducted to validate the identified markers. The goal is to develop specific treatment recommendations based on the findings.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with stage I, II, IIIA, or IIIB NSCLC who have undergone surgical treatment at Georges Pompidou Hospital.
Not a fit: Patients who have not signed the informed consent for the ONCOHEGP project will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic tools and personalized treatment strategies for patients with localized NSCLC.
How similar studies have performed: Other studies have shown success in identifying molecular signatures in cancer, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with NSCLC stage I II IIIA IIIB, treated by surgery at Georges Pompidou Hospital (HEGP) Informed consent ONCOHEGP signed Exclusion Criteria: * Informed consent ONCOHEGP not signed
Where this trial is running
Paris
- Aphp Hegp — Paris, France (Recruiting)
Study contacts
- Principal investigator: Francoise Lepimpec Barthes, MD PhD — Aphp
- Study coordinator: Helene BLONS, PharmD PhD
- Email: helene.blons@aphp.fr
- Phone: 00 33 156095686
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.